A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077BRITTEN, C. D; ROWINSKY, E. K; VON HOFF, D. D et al.Clinical cancer research. 2000, Vol 6, Num 1, pp 42-49, issn 1078-0432Article

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma : a Southwest Oncology Group studyDALTON, W. S; CROWLEY, J. J; SALMON, S. S et al.Cancer. 1995, Vol 75, Num 3, pp 815-820, issn 0008-543XArticle

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapyBEDIKIAN, A. Y; WEISS, G. R; BENJAMIN, R. S et al.Journal of clinical oncology. 1995, Vol 13, Num 12, pp 2895-2899, issn 0732-183XArticle

A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaHAWKINS, M. J; ATKINS, M. B; GAYNOR, E. R et al.Journal of immunotherapy. 1994, Vol 15, Num 1, pp 74-78, issn 1053-8550Article

Phase I and pharmacokinetic trial of weekly CPT-11ROTHENBERG, M. L; KUHN, J. G; ROCK, M. K et al.Journal of clinical oncology. 1993, Vol 11, Num 11, pp 2194-2204, issn 0732-183XArticle

Intrapleural therapy for malignant pleural effusions : a randomized comparison of bleomycin and tetracyclineRUCKDESCHEL, J. C; MOORES, D; LEE, J. Y et al.Chest. 1991, Vol 100, Num 6, pp 1528-1535, issn 0012-3692Article

Phase I and clinical pharmacology trial of 502U83 using a monthly single dose scheduleVON HOFF, D. D; KUHN, J. G; WARGIN, W et al.Cancer research (Baltimore). 1990, Vol 50, Num 23, pp 7496-7500, issn 0008-5472, 5 p.Article

Miscellaneous anticancer drugsKISNER, D. L; KUHN, J. G; WEISS, G. R et al.Cancer chemotherapy. 1983, Num 5, pp 161-170Article

A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposideHAMMOND, L. A; ECKARDT, J. R; VON HOFF, D. D et al.Clinical cancer research. 1998, Vol 4, Num 6, pp 1459-1467, issn 1078-0432Article

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerROTHENBERG, M. L; ECKARDT, J. R; WEISS, G. R et al.Journal of clinical oncology. 1996, Vol 14, Num 4, pp 1128-1135, issn 0732-183XArticle

Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation : a Southwest Oncology Group StudyKELLY, K; CROWLEY, J. J; LIVINGSTON, R et al.Journal of clinical oncology. 1995, Vol 13, Num 12, pp 2924-2930, issn 0732-183XArticle

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaWEISS, G. R; MARGOLIN, K. A; HAWKINS, M. J et al.Journal of clinical oncology. 1992, Vol 10, Num 2, pp 275-281, issn 0732-183XArticle

A randomized phase II trial of trimetexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix : a southwest oncology group trialWEISS, G. R; LIU, P. Y; O'SULLIVAN, J et al.Gynecologic oncology (Print). 1992, Vol 45, Num 3, pp 303-306, issn 0090-8258Article

Malignant melanoma in a Hispanic male with nevus of otaSHAFFER, D; WALKER, K; WEISS, G. R et al.Dermatology. 1992, Vol 185, Num 2, pp 146-150Article

Phase I clinical and pharmacokinetic trial of flavone acetic acidHAVLIN, K. A; KUHN, J. G; CRAIG, B et al.Journal of the National Cancer Institute. 1991, Vol 83, Num 2, pp 124-128, issn 0027-8874, 5 p.Article

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinomaGAYNOR, E. R; WEISS, G. R; BAR, M. H et al.Journal of the National Cancer Institute. 1990, Vol 82, Num 17, pp 1397-1402, issn 0027-8874Article

Phase I trial of echinomycin (NSG 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusionKUHN, J. G; VON HOFF, D. D; HERSH, M et al.European journal of cancer & clinical oncology. 1989, Vol 25, Num 5, pp 797-803, issn 0277-5379Article

Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignanciesHAMMOND, L. A; ECKARDT, J. R; VON HOFF, D. D et al.Journal of clinical oncology. 1999, Vol 17, Num 8, pp 2604-2613, issn 0732-183XArticle

A phase I and pharmacokinetic study of tallimustine [PNU152241 (FCE 24517)] in patients with advanced cancerWEISS, G. R; POGGESI, I; O'DWYER, P et al.Clinical cancer research. 1998, Vol 4, Num 1, pp 53-59, issn 1078-0432Article

A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinomaWEISS, G. R; MARGOLIN, K. A; FISHER, R. I et al.Journal of immunotherapy with emphasis on tumor immunology. 1995, Vol 18, Num 1, pp 52-56, issn 1067-5582Article

A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogarilWEISS, G. R; BROWN, T. D; KUHN, J. G et al.Investigational new drugs. 1993, Vol 11, Num 1, pp 17-27, issn 0167-6997Article

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomasANTMAN, K; CROWLEY, J; DOROSHOW, J. H et al.Journal of clinical oncology. 1993, Vol 11, Num 7, pp 1276-1285, issn 0732-183XArticle

New anticancer agentsWEISS, G. R; BURRIS, H. A; ECKARDT, J. R et al.Cancer chemotherapy and biological response modifiers annual. 1993, Vol 14, pp 118-128, issn 0921-4410Article

Southwest oncology group standard response criteria, endpoint definitions and toxicity criteriaGREEN, S; WEISS, G. R.Investigational new drugs. 1992, Vol 10, Num 4, pp 239-253, issn 0167-6997Article

An outbreak of hepatitis B among cancer patients treated with interleukin-2 and lymphokine-activated killer cellsWEISFUSE, I. B; GRAHAM, D. J; MILLS, B. J et al.The Journal of infectious diseases. 1990, Vol 161, Num 4, pp 647-652, issn 0022-1899Article